Prediction of poor outcome in CLL patients following first-line
treatment with fludarabine, cyclophosphamide and rituximab

J 2013

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

FINK, A. M., S. BOTTCHER, M. RITGEN, K. FISCHER, N. PFLUG et. al.

Základní údaje

Originální název

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Autoři

FINK, A. M. (276 Německo), S. BOTTCHER (276 Německo), M. RITGEN (276 Německo), K. FISCHER (276 Německo), N. PFLUG (276 Německo), B. EICHHORST (276 Německo), C. M. WENDTNER (276 Německo), A. BUHLER (276 Německo), T. ZENZ (276 Německo), P. STAIB (276 Německo), Jiří MAYER (203 Česká republika, garant, domácí), M. HENSEL (276 Německo), G. HOPFINGER (40 Rakousko), Marie WENGER (756 Švýcarsko), G. FINGERLE-ROWSON (276 Německo), H. DOHNER (276 Německo), M. KNEBA (276 Německo), S. STILGENBAUER (276 Německo), R. BUSCH (276 Německo), M. HALLEK (276 Německo) a D. WINKLER (276 Německo)

Vydání

Leukemia, LONDON, NATURE PUBLISHING GROUP, 2013, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 9.379

Kód RIV

RIV/00216224:14110/13:00070501

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/leu.2013.190

UT WoS

000324162700029

Klíčová slova anglicky

CHRONIC LYMPHOCYTIC-LEUKEMIA; TRIAL; SURVIVAL; QUANTIFICATION; PROGRESSION

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2014 13:18, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL).1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory2 and might be associated with a shortened overall survival.

Citovat

FINK, A. M., S. BOTTCHER, M. RITGEN, K. FISCHER, N. PFLUG, B. EICHHORST, C. M. WENDTNER, A. BUHLER, T. ZENZ, P. STAIB, Jiří MAYER, M. HENSEL, G. HOPFINGER, Marie WENGER, G. FINGERLE-ROWSON, H. DOHNER, M. KNEBA, S. STILGENBAUER, R. BUSCH, M. HALLEK a D. WINKLER. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. LONDON: NATURE PUBLISHING GROUP, 2013, roč. 27, č. 9, s. 1949-1952. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2013.190.

@article{1136283,
   author = {Fink, A. M. and Bottcher, S. and Ritgen, M. and Fischer, K. and Pflug, N. and Eichhorst, B. and Wendtner, C. M. and Buhler, A. and Zenz, T. and Staib, P. and Mayer, Jiří and Hensel, M. and Hopfinger, G. and Wenger, Marie and FingerleandRowson, G. and Dohner, H. and Kneba, M. and Stilgenbauer, S. and Busch, R. and Hallek, M. and Winkler, D.},
   article_location = {LONDON},
   article_number = {9},
   doi = {http://dx.doi.org/10.1038/leu.2013.190},
   keywords = {CHRONIC LYMPHOCYTIC-LEUKEMIA; TRIAL; SURVIVAL; QUANTIFICATION; PROGRESSION},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab},
   volume = {27},
   year = {2013}
}

TY  - JOUR
ID  - 1136283
AU  - Fink, A. M. - Bottcher, S. - Ritgen, M. - Fischer, K. - Pflug, N. - Eichhorst, B. - Wendtner, C. M. - Buhler, A. - Zenz, T. - Staib, P. - Mayer, Jiří - Hensel, M. - Hopfinger, G. - Wenger, Marie - Fingerle-Rowson, G. - Dohner, H. - Kneba, M. - Stilgenbauer, S. - Busch, R. - Hallek, M. - Winkler, D.
PY  - 2013
TI  - Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
JF  - Leukemia
VL  - 27
IS  - 9
SP  - 1949-1952
EP  - 1949-1952
PB  - NATURE PUBLISHING GROUP
SN  - 08876924
KW  - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW  - TRIAL
KW  - SURVIVAL
KW  - QUANTIFICATION
KW  - PROGRESSION
N2  - Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL).1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory2 and might be associated with a shortened overall survival.
ER  -

FINK, A. M., S. BOTTCHER, M. RITGEN, K. FISCHER, N. PFLUG, B. EICHHORST, C. M. WENDTNER, A. BUHLER, T. ZENZ, P. STAIB, Jiří MAYER, M. HENSEL, G. HOPFINGER, Marie WENGER, G. FINGERLE-ROWSON, H. DOHNER, M. KNEBA, S. STILGENBAUER, R. BUSCH, M. HALLEK a D. WINKLER. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. \textit{Leukemia}. LONDON: NATURE PUBLISHING GROUP, 2013, roč.~27, č.~9, s.~1949-1952. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/leu.2013.190.

Podrobný výpis o publikaci